Objective: Provide direction to pharmacists on preparing to meet the compliance standards of the Drug Supply Chain and Security Act (DSCSA), which is scheduled to take full effect by Nov. 27, 2023.

DSCSA Overview:
The DSCSA, Title II of the Drug Quality and Security Act (DQSA) enacted by the United States Congress on Nov. 27, 2013, sets forth requirements for trading partners (i.e., manufacturers, wholesale distributors, repackagers, dispensers, and third-party logistics providers) regarding the tracing of prescription pharmaceutical products during distribution throughout the United States. These interoperable, electronic tracing systems will allow the Food and Drug Administration (FDA) to protect U.S. consumers by readily identifying compromised prescription pharmaceutical products, including those that may be counterfeit, stolen, contaminated, dangerous, or harmful, and removing them from the pharmaceutical supply chain. In addition, the DSCSA will require wholesale distributors and third-party logistics providers to obtain national licensure and report licensure status to the FDA annually.

What are the Responsibilities of Pharmacists (“Dispensers”) Under DSCSA?
The DSCSA defines a dispenser as “a retail pharmacy, hospital pharmacy, a group of chain pharmacies under common ownership and control that do not act as a wholesale distributor, or any other person authorized by law to dispense or administer prescription drugs, and the affiliated warehouses or distribution centers of such entities under common ownership and control that do not act as a wholesale distributor and does not include a person who dispenses only products to be used in animals in accordance with section 512(a)(5).”

Special acknowledgment to Renee Mott, PharmD, PGY2 Health-System Pharmacy Administration & Leadership Resident, MedStar Health, Inc.; Raymond Lake, MS, RPh, Corporate Director of Pharmacy Operations, MedStar Health, Inc.; and Joe Maki, PharmD, MS, Vice President, Pharmacy, Novant Health for their contributions in developing this document.
Current Responsibility Overview:
The key responsibilities of pharmacists in 2022 under DSCSA are:4,5 As of the end of 2022, pharmacists must ensure most products are traceable at the lot-level and the following key responsibilities are met:

1. Engage in business only with licensed, registered trading partners:
   a. Manufacturers and repackagers are required to have a current registration
   b. Wholesale distributors and third-party logistics providers are required to be licensed

2. Properly manage product tracing documentation:
   a. Only accept prescription pharmaceutical products if they arrive with the transaction history (TH),* transaction information (TI), and transaction statements (TS)
   b. All product tracing information must be kept in a secure format for six years
   c. When selling prescription pharmaceutical products to a trading partner, include most product tracing information with the transaction

*As of Nov. 23, 2023, the TH requirement expires and has “no force or effect.”6

3. Implement a system and process to properly manage suspect and illegitimate prescription pharmaceutical products
   a. Quarantine any suspect prescription pharmaceutical product(s)
   b. Collaborate with the manufacturer of suspect or illegitimate prescription pharmaceutical product(s) to ensure patients do not receive the illegitimate product(s)
   c. Report findings of illegitimate prescription pharmaceutical product(s) to the FDA and involved trading partners

New Responsibilities for 2023:
By 2023, pharmacists should ensure that their organization has policies and procedures in place that allow for unit-level traceability under DSCSA, including:3,5

1. Ensuring that all required TI and TS are exchanged between trading partners via a secure, interoperable, electronic system
2. Checking for inclusion of a package identifier (PI) to identify the prescription pharmaceutical product at the package level
3. Verifying the product identifier on a package or sealed case by the trading partners via a secure, interoperable, electronic system is available
4. Ensuring that trading partners can provide TI and TS via a secure, interoperable, electronic system when requested by authorized agents
5. Ensuring that secure, interoperable, electronic systems allow for the prompt production of TI for each transaction going back to the manufacturer
6. Addressing saleable returns by ensuring that secure, interoperable, electronic systems are in place and the TI and TS are returned with the product
Advice to Practitioners

Key Considerations for DSCSA Compliance
1. Educate staff regarding DSCSA requirements
2. Purchase prescription pharmaceutical products only from verified primary wholesale distributors or manufacturers
3. Develop organizational policies and procedures for addressing DSCSA dispenser requirements, including:
   a. Ensuring most received prescription pharmaceutical product shipments contain tracing information (TI and TS)
   b. Verifying product appearance of prescription pharmaceutical products when they arrive on site, to include attention to proper spelling/labeling, terminology, lot number, and expiration date, checking for holograms or other indicia of legitimacy
   c. Managing suspect and illegitimate prescription pharmaceutical products, including a quarantine process
   d. Reporting suspect or illegitimate product to the FDA and responding to an FDA inquiry within 48 hours of receipt
   e. Ensuring transaction data is being safely stored
4. Establish clear expectations for vendors regarding DSCSA compliance

Five things to discuss with your partner(s):
1. Does your wholesale distributor transact serialized product?
2. How are you preparing for DSCSA 2023 compliance?
3. Are you prepared for full prescription pharmaceutical product traceability in a secure, electronic, interoperable manner?
4. What will you expect from dispensers in 2023?
5. Determine which of your key vendors have this on their radar (inventory vendor, EMR vendor, tracing data vendor, etc.)

Three things you should be doing now to prepare for DSCSA 2023:
1. Identifying a team to be charged with 2023 compliance preparedness. Team members may include members from Pharmacy, IT, Compliance, and Legal
2. Assessing technology needs
3. Revisiting compliance with current standards to determine where you are positioned for 2023
In Summary:
By Nov. 23, 2023:

1. Policies and procedures must be in place to allow for unit-level traceability (i.e., product identification) of most prescription pharmaceutical products
2. All communications between trading partners, authorities, and dispensers must be conducted via a secure, interoperable, electronic system

References:


Disclaimer: The information contained in this guide is provided for informational purposes. It is not to be considered as medical, legal, or other professional advice. The information contained in this guide is provided solely on an “as is” basis, without any representations or warranties, express or implied. No recipients or readers of this guide should act or refrain from acting on the basis of any content included in this guide. The content of this guide contains general information only, and may not reflect the most current standards, legal developments, regulations or laws. ASHP makes no representation or warranty with respect to this guide and the information contained herein, and expressly disclaims any and all liability with respect to it, including, but not limited to, a) the accuracy and/or completeness of the information contained in this guide; and b) the consequences of actions taken or not taken based on any or all the contents of the guide. The contents of the guide address topics of interest to our membership and other audiences, and are offered solely on a blind basis, without any knowledge as to specific circumstances. The application and impact of relevant laws and regulations will vary from jurisdiction to jurisdiction. The content of this guide should not be relied upon or used as a substitute for consultation with professional advisers.
Additional Resources

1. ASHP Drug Supply Chain Resource: https://www.ashp.org/dscsa?loginreturnUrl=SSOCheckOnly
5. Decision Tree Graphic: Should this Drug Package or Case Have a Product Identifier Under the DSCSA?: https://www.fda.gov/media/116363/download
15. FDA Website: Know Your Source: Protecting Patients from Unsafe Drugs: http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm389121.htm
16. FDA Email Contacts: DrugTrackandTrace@fda.hhs.gov CDERDrugSupplyChainIntegrity@fda.hhs.gov WDD3PLRequirements@fda.hhs.gov